Journal of Clinical Oncology

Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters

C Christina T. Muijs (Christina T. Muijs, MD, PhD, Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands, Maaike Berbee, MD, PhD, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands, Peter S.N. van Rossum, MD, PhD, Department of Radiation Oncology, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands, Nadia Haj Mohammad, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Bas Wijnhoven, MD, PhD, Department of Surgery, Erasmus University Medical Center, University of Rotterdam, Rotterdam, the Netherlands, Hanneke W.M. Van Laarhoven, MD, PhD, Department of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands, Karin M. Haustermans, MD, PhD, Department of Radiation Oncology, KU Leuven, Leuven University, Leuven, Belgium) M Maaike Berbee P Peter S.N. van Rossum (Christina T. Muijs, MD, PhD, Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands, Maaike Berbee, MD, PhD, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands, Peter S.N. van Rossum, MD, PhD, Department of Radiation Oncology, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands, Nadia Haj Mohammad, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Bas Wijnhoven, MD, PhD, Department of Surgery, Erasmus University Medical Center, University of Rotterdam, Rotterdam, the Netherlands, Hanneke W.M. Van Laarhoven, MD, PhD, Department of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands, Karin M. Haustermans, MD, PhD, Department of Radiation Oncology, KU Leuven, Leuven University, Leuven, Belgium) N Nadia Haj Mohammad (Christina T. Muijs, MD, PhD, Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands, Maaike Berbee, MD, PhD, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands, Peter S.N. van Rossum, MD, PhD, Department of Radiation Oncology, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands, Nadia Haj Mohammad, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Bas Wijnhoven, MD, PhD, Department of Surgery, Erasmus University Medical Center, University of Rotterdam, Rotterdam, the Netherlands, Hanneke W.M. Van Laarhoven, MD, PhD, Department of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands, Karin M. Haustermans, MD, PhD, Department of Radiation Oncology, KU Leuven, Leuven University, Leuven, Belgium) B Bas Wijnhoven (Christina T. Muijs, MD, PhD, Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands, Maaike Berbee, MD, PhD, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands, Peter S.N. van Rossum, MD, PhD, Department of Radiation Oncology, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands, Nadia Haj Mohammad, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Bas Wijnhoven, MD, PhD, Department of Surgery, Erasmus University Medical Center, University of Rotterdam, Rotterdam, the Netherlands, Hanneke W.M. Van Laarhoven, MD, PhD, Department of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands, Karin M. Haustermans, MD, PhD, Department of Radiation Oncology, KU Leuven, Leuven University, Leuven, Belgium) H Hanneke W.M. van Laarhoven K Karin M. Haustermans (Christina T. Muijs, MD, PhD, Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands, Maaike Berbee, MD, PhD, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands, Peter S.N. van Rossum, MD, PhD, Department of Radiation Oncology, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands, Nadia Haj Mohammad, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Bas Wijnhoven, MD, PhD, Department of Surgery, Erasmus University Medical Center, University of Rotterdam, Rotterdam, the Netherlands, Hanneke W.M. Van Laarhoven, MD, PhD, Department of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands, Karin M. Haustermans, MD, PhD, Department of Radiation Oncology, KU Leuven, Leuven University, Leuven, Belgium)
View Original
APA MLA Chicago BibTeX RIS

Article Details

Volume / Issue Vol. 44, Issue 15
Published May 20, 2026
Pages 1465-1467
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins
ISSN: 0732-183X Health Sciences

Authors (7)

C

Christina T. Muijs

Christina T. Muijs, MD, PhD, Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands, Maaike Berbee, MD, PhD, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands, Peter S.N. van Rossum, MD, PhD, Department of Radiation Oncology, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands, Nadia Haj Mohammad, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Bas Wijnhoven, MD, PhD, Department of Surgery, Erasmus University Medical Center, University of Rotterdam, Rotterdam, the Netherlands, Hanneke W.M. Van Laarhoven, MD, PhD, Department of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands, Karin M. Haustermans, MD, PhD, Department of Radiation Oncology, KU Leuven, Leuven University, Leuven, Belgium

M

Maaike Berbee

P

Peter S.N. van Rossum

Christina T. Muijs, MD, PhD, Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands, Maaike Berbee, MD, PhD, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands, Peter S.N. van Rossum, MD, PhD, Department of Radiation Oncology, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands, Nadia Haj Mohammad, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Bas Wijnhoven, MD, PhD, Department of Surgery, Erasmus University Medical Center, University of Rotterdam, Rotterdam, the Netherlands, Hanneke W.M. Van Laarhoven, MD, PhD, Department of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands, Karin M. Haustermans, MD, PhD, Department of Radiation Oncology, KU Leuven, Leuven University, Leuven, Belgium

N

Nadia Haj Mohammad

Christina T. Muijs, MD, PhD, Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands, Maaike Berbee, MD, PhD, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands, Peter S.N. van Rossum, MD, PhD, Department of Radiation Oncology, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands, Nadia Haj Mohammad, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Bas Wijnhoven, MD, PhD, Department of Surgery, Erasmus University Medical Center, University of Rotterdam, Rotterdam, the Netherlands, Hanneke W.M. Van Laarhoven, MD, PhD, Department of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands, Karin M. Haustermans, MD, PhD, Department of Radiation Oncology, KU Leuven, Leuven University, Leuven, Belgium

B

Bas Wijnhoven

Christina T. Muijs, MD, PhD, Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands, Maaike Berbee, MD, PhD, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands, Peter S.N. van Rossum, MD, PhD, Department of Radiation Oncology, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands, Nadia Haj Mohammad, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Bas Wijnhoven, MD, PhD, Department of Surgery, Erasmus University Medical Center, University of Rotterdam, Rotterdam, the Netherlands, Hanneke W.M. Van Laarhoven, MD, PhD, Department of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands, Karin M. Haustermans, MD, PhD, Department of Radiation Oncology, KU Leuven, Leuven University, Leuven, Belgium

H

Hanneke W.M. van Laarhoven

K

Karin M. Haustermans

Christina T. Muijs, MD, PhD, Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands, Maaike Berbee, MD, PhD, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands, Peter S.N. van Rossum, MD, PhD, Department of Radiation Oncology, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands, Nadia Haj Mohammad, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Bas Wijnhoven, MD, PhD, Department of Surgery, Erasmus University Medical Center, University of Rotterdam, Rotterdam, the Netherlands, Hanneke W.M. Van Laarhoven, MD, PhD, Department of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands, Karin M. Haustermans, MD, PhD, Department of Radiation Oncology, KU Leuven, Leuven University, Leuven, Belgium

Related Articles from this Journal

Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Ismaela Anna Vascotto, Filippo Antonica et al. Aug 2026 10.1200/jco-26-00658

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Samer A. Srour, Jad Chahoud et al. Aug 2026 10.1200/jco-26-00388

Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection

Risako Komata, Kenju Ando et al. Aug 2026 10.1200/jco-26-00140

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

Ghayas C. Issa, Branko Cuglievan et al. Aug 2026 10.1200/jco-26-01743

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Irbaz Bin Riaz, R. Bryan Rumble et al. Aug 2026 10.1200/jco-26-01001